Business
The worst mistake Moderna investors can make right now
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
In late 2018, Moderna Inc (NASDAQ: MRNA) went public in the largest biotech initial public offering (IPO) in history. Its value barely moved until mid-February 2020, when COVID-19 cases in the U.S. started showing up in multiple states. Now that its coronavirus vaccine has received Emergency Use Authorization, some investors might think there is limited upside left in the stock. That thinking might lead shareholders of Moderna to do the worst thing they could do right now.
Warp speed and beyond
Working with the National Institute of Allergy and Infectious Diseases, the company delivered a vaccine just 42 days after the…
-
General19 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business18 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General20 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General21 hours agoAlbanese beats drum on economy as trade clouds gather